Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis

Table 1 Quality of studies reviewed

Name of publication of study	Yr	Random-ization?	Similar groups initially?	Equal treatments?	All participants accounted for?	Analyzed in groups to which they were randomized?	Objective/“blind” treatments?	Overall quality of the study
Meltzer et al[23]	2010	Yes	Yes	Yes	Yes	Yes	Yes	Good
Cummings et al[24]	2014	Yes	Yes	Yes	Yes	Yes	Yes	Good

Table 2 Summary of studies

Name of study	Yr	Country of origin	Total number of participants	Age	Type of setting	Comparators	Duration
Meltzer et al[23]	2010	United States	60	Mean age 70.9 yr	Unclear	Pimavanserin vs placebo	4 wk
Cummings et al[24]	2014	United States and Canada	199	Mean age 72.4 yr	Academic hospitals and neurology research centers	Pimavanserin vs placebo	6 wk